Table 1.
Baseline Characteristic of Patients
| SAIR group | |||||
|---|---|---|---|---|---|
| Characteristic | All | SAP therapy | MDIs + CGM | CSII + SMBG group | MDIs + SMBG group |
| No. | 27 | 15 | 12 | 20 | 18 |
| Male [n (%)] | 16 (59) | 9 (60) | 7 (58) | 11 (55) | 9 (50) |
| Age (years) | 34 ± 10 | 33 ± 10 | 34 ± 10 | 35 ± 9 | 38 ± 17 |
| Duration of diabetes (years) | 15 ± 9 | 15 ± 9 | 16 ± 10 | 13 ± 10 | 14 ± 9 |
| HbA1c (mmol/mol) | 67.5 ± 10 | 66 ± 9 | 69.3 ± 8 | 67.9 ± 9 | 67.2 ± 9 |
| HbA1c (%) | 8.3 ± 9 | 8.2 ± 0.9 | 8.5 ± 1.1 | 8.4 ± 0.8 | 8.3 ± 0.8 |
| Mean sensor glucose (mmol/L) | 10.7 ± 1.5 | 10.4 ± 1.4 | 10.9 ± 1.6 | 10.7 ± 1.2 | 10.6 ± 1.4 |
| BMI (kg/m2) | 25 ± 3 | 25 ± 3 | 25 ± 3 | 26 ± 4 | 24 ± 3 |
Values are presented as mean ± SD, P values <0.05 are statistically significant.
CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin infusion; MDIs, multiple daily injections; SAIR, sensor-augmented insulin regimen; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose.